Meet Friedrich Finckenstein


Friedrich Finckenstein joined Roche pRED in November 2015 as Global Head of Oncology Translational Medicine from Bristol-Myers Squibb Co (BMS) where since 2012, he was Medical Group Director, Global Clinical Research. In this role Friedrich worked on the clinical development of Cancer Immunotherapy with a focus on non-small cell lung cancer (NSCLC).

Prior to this role, Friedrich had roles of increasing responsibility in the early clinical development and translational research group at BMS, which he joined in 2006. He led several cross-functional teams responsible for planning and operation of asset development between identification of clinical candidates to Go-to-Phase IIb decisions.

Friedrich received his MD from the University of Hamburg, Germany, and is a board certified pediatrician. His clinical work focused on Pediatric Hematology/Oncology. Friedrich conducted basic cancer research as a postdoctoral fellow at the Ludwig Institute for Cancer Research, San Diego Branch; as a Research Scholar at the Children’s Hospital Los Angeles; and during his clinical appointment at University Children’s Hospital, Hamburg, Germany.